Targeting cancer cell dormancy.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 38062251.
- Also identified by DOI 10.1038/s41568-023-00642-x and PMC identifier 11038906.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The field of tumour dormancy, originally defined as a clinical phenomenon of late recurrence after a long, apparently disease-free period, has seen significant advances that now allow us to think about monitoring and targeting dormant tumour cells to prevent relapse. In this Viewpoint article, we asked experts to share their views on the steps that are needed to translate dormancy research into the clinic.
Medical subject headings
- Neoplasms